Background： Safflower extract and aceglutamide （SA） has been used clinically for the treatment of cerebrovascular diseases such as cerebral embolism, hemorrhage, and mental deterioration. This study aimed to invest...Background： Safflower extract and aceglutamide （SA） has been used clinically for the treatment of cerebrovascular diseases such as cerebral embolism, hemorrhage, and mental deterioration. This study aimed to investigate the effect and mechanism of SA injection in the recovery of peripheral innervations of diabetic mice. Methods： The C57BL/6 male mice were divided into four groups： normal control group （n = 44）, diabetic group （n = 44）, diabetic ＋ SA group （diabetic mice treated with SA injection, n = 44）, and diabetic ＋ SA ＋ vascular endothelial growth factor receptor （VEGFR）1-BL group （diabetic mice treated with SA injection and VEGFR 1 blocking antibody n = 24）. The streptozotocin-induced diabetic mice model and injured peripheral nerve mice model were built. The mice with injured peripheral nerves were intraperitonealy administered with SA injection for successive 21 days. The corneal sensitivity, number of corneal nerve fibers, and contents of vascular endothelial growth factor （VEGF）-B and various neurotrophic factors such as nerve growth factor （NGF） and glial cell line-derived neurotrophic factor （GDNF） in corneal tissue of four groups were observed. Results： The diabetic group showed decreased number of corneal nerve fibers, compared with the control group （P = 0.002）. And compared with the diabetic group, the diabetic ＋ SA group showed a significant increase in the number of nerve fibers （P = 0.024） and the contents of VEGF-B,NGF,andGDNFinthecornea（allP〈0.05）.However,whenthediabeticmiceweretreatedwiththeblockingantibodiesspecializedfor VEGF-B receptor, the neutralization ofVEGFR-1 completely abolished the increased expression of NGF and GDNF stimulated by SAinjection. Conclusions： SA injection could reduce the nerve injury caused by diabetic peripheral neuropathy, and its protective effect might be associated with the promotion of the expressions of VEGF-B, NGF, and GDNF.展开更多
目的探究谷红注射液联合复方脑肽节苷脂注射液在腔隙性脑梗死患者治疗中的应用效果。方法选取2019年6月—2023年6月在江苏省盱眙县中医院老年病科接受相应治疗的80例腔隙性脑梗死患者为研究对象。按照入院时间排序,把1~40号患者作为对照...目的探究谷红注射液联合复方脑肽节苷脂注射液在腔隙性脑梗死患者治疗中的应用效果。方法选取2019年6月—2023年6月在江苏省盱眙县中医院老年病科接受相应治疗的80例腔隙性脑梗死患者为研究对象。按照入院时间排序,把1~40号患者作为对照组,施行谷红注射液+盐酸倍他司汀注射液治疗,41~80号患者作为观察组,施行谷红注射液+复方脑肽节苷脂注射液治疗。对比两组患者在卒中量表(National Institute of Heslth Stroke Scale,NIHSS)评分、活动能力量表(Activity of Daily Living,ADL)评分以及不良反应中的差异,比较分析谷红注射液与复方脑肽节苷脂注射液的联合应用可行性。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,相较于对照组,观察组NIHSS评分更低,ADL评分更高,差异有统计学意义(P<0.05);观察组不良反应发生率(7.50%)与对照组(12.50%)比较,差异无统计学意义(χ^(2)=0.556,P=0.456)。结论面对腔隙性脑梗死患者,临床运用谷红注射液与复方脑肽节苷脂注射液联合治疗,显著提高治疗效果,纠正神经功能状态,增强机体自理能力,且不会增加患者不良反应发生风险,安全价值高。展开更多
基金This study was supported by grants from Shandong Provincial Natural Science Foundation, China （No. ZR2016HPI 7）, the Project of Medical and Health Technology Development Program in Shandong Province （No. 2016WS0282）, and Qingdao Postdoctoral Application Research Funded Project （No. 2016063）.
文摘Background： Safflower extract and aceglutamide （SA） has been used clinically for the treatment of cerebrovascular diseases such as cerebral embolism, hemorrhage, and mental deterioration. This study aimed to investigate the effect and mechanism of SA injection in the recovery of peripheral innervations of diabetic mice. Methods： The C57BL/6 male mice were divided into four groups： normal control group （n = 44）, diabetic group （n = 44）, diabetic ＋ SA group （diabetic mice treated with SA injection, n = 44）, and diabetic ＋ SA ＋ vascular endothelial growth factor receptor （VEGFR）1-BL group （diabetic mice treated with SA injection and VEGFR 1 blocking antibody n = 24）. The streptozotocin-induced diabetic mice model and injured peripheral nerve mice model were built. The mice with injured peripheral nerves were intraperitonealy administered with SA injection for successive 21 days. The corneal sensitivity, number of corneal nerve fibers, and contents of vascular endothelial growth factor （VEGF）-B and various neurotrophic factors such as nerve growth factor （NGF） and glial cell line-derived neurotrophic factor （GDNF） in corneal tissue of four groups were observed. Results： The diabetic group showed decreased number of corneal nerve fibers, compared with the control group （P = 0.002）. And compared with the diabetic group, the diabetic ＋ SA group showed a significant increase in the number of nerve fibers （P = 0.024） and the contents of VEGF-B,NGF,andGDNFinthecornea（allP〈0.05）.However,whenthediabeticmiceweretreatedwiththeblockingantibodiesspecializedfor VEGF-B receptor, the neutralization ofVEGFR-1 completely abolished the increased expression of NGF and GDNF stimulated by SAinjection. Conclusions： SA injection could reduce the nerve injury caused by diabetic peripheral neuropathy, and its protective effect might be associated with the promotion of the expressions of VEGF-B, NGF, and GDNF.
文摘目的探究谷红注射液联合复方脑肽节苷脂注射液在腔隙性脑梗死患者治疗中的应用效果。方法选取2019年6月—2023年6月在江苏省盱眙县中医院老年病科接受相应治疗的80例腔隙性脑梗死患者为研究对象。按照入院时间排序,把1~40号患者作为对照组,施行谷红注射液+盐酸倍他司汀注射液治疗,41~80号患者作为观察组,施行谷红注射液+复方脑肽节苷脂注射液治疗。对比两组患者在卒中量表(National Institute of Heslth Stroke Scale,NIHSS)评分、活动能力量表(Activity of Daily Living,ADL)评分以及不良反应中的差异,比较分析谷红注射液与复方脑肽节苷脂注射液的联合应用可行性。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,相较于对照组,观察组NIHSS评分更低,ADL评分更高,差异有统计学意义(P<0.05);观察组不良反应发生率(7.50%)与对照组(12.50%)比较,差异无统计学意义(χ^(2)=0.556,P=0.456)。结论面对腔隙性脑梗死患者,临床运用谷红注射液与复方脑肽节苷脂注射液联合治疗,显著提高治疗效果,纠正神经功能状态,增强机体自理能力,且不会增加患者不良反应发生风险,安全价值高。
